Recent Preliminary Trial Data of Covid-19 Vaccine From Germany; 'Very effective.'

Recent Preliminary Trial Data of Covid-19 Vaccine From Germany; 'Very effective.'

Good news for all of us!

The latest vaccine developed by the German company BioNTech and its partner Pfizer is 90% effective in preventing COVID-19 infection, according to a 3rd phase trial.

More than 43,500 people participated in this experiment which has been going on since last July. Both companies are to get approval with the U.S. Food and Drug Administration in the next few weeks.

This phase 3 time is still running, and any other additional data may have a different effect. It is, to some extent relieving to all of us to see the progress made by researchers around the world.


How is the Phase 3 Trial Conducted?

The company told that a preliminary analysis of the results showing individuals who received two doses of this vaccine for three weeks experienced 90% less Covid-19 symptomatic compare to those with placebo (a substance with no therapeutic effect).

They will not, however, distribute this vaccine for emergency cases until they reach another milestone that is when half of the patients in their study were free from any safety concerns at least two months after their second injection dose.

Pfizer expects to pass that level in the third week of November. Pfizer expects to give the drink in the third week of November.

According to a report in The New York Time, in the case of their vaccine approved, Pfizer and BioNTech hope to produce more than 1.3 billion doses of their vaccine worldwide by the end of 2021.


We Still Have to Wait for Additional Data

Without further information about this vaccine, it is still too early to predict the impact this vaccine can have. "I do not want to drop the potential for this vaccine. I just want us to be realistic," said Michael Osterholm, University of Minnesota Center Director for Infectious Diseases Research and Policy.

He added "For a vaccine to have maximum effect, it also needs to reduce chronic disease and death. We still do not know it completely."

Despite that, this vaccine is one of the vaccines with the best potential. However, they still need to find out how long this vaccine can protect a person from this virus before it strikes back.

Bourla, CEO of Pfizer said, the results of this study are "a good day for science and humanity" and he promised to share information and safety data to the public in a few weeks.


This news is good progress for all of us. Covid-19 is a crisis that not only threatens the health but the economy of the whole world. So let us all pray that good news will be announced later as well as to carry out our responsibility always to practice social distance, wear masks and ensure our hygiene.